When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.
The US regulator has come down surprisingly hard on biotech stock promotion schemes.